Motility & Functional GI · Article 121

How Should GLP-1 Receptor Agonists Be Managed Before Endoscopy?

GLP-1 endoscopy requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

GLP-1 endoscopy clinical reference — Related free clinical resource: Clinical Pharmacology.

GLP-1 endoscopy: practical clinical approach

This page focuses on GLP-1 endoscopy with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for GLP-1 endoscopy

Clinical takeaway: For GLP-1 endoscopy, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: Routine blanket discontinuation of GLP-1 receptor agonists before endoscopy is not supported by current GI and perioperative guidance. Most asymptomatic patients who have followed appropriate fasting instructions can proceed. Risk is higher during dose escalation, with significant nausea, vomiting, bloating, constipation, high doses, known gastroparesis or other disorders that delay gastric emptying. In higher-risk patients, a 24-hour liquid-only diet, procedure delay, anesthesia modification or other precautions may be appropriate. The decision should balance aspiration risk against the consequences of interrupting diabetes or obesity treatment.

Why the issue matters

GLP-1 receptor agonists and dual incretin agents can delay gastric emptying, especially early in treatment and during dose escalation. Retained gastric contents may complicate upper endoscopy and theoretically increase regurgitation and aspiration risk during deep sedation or anesthesia.

Current approach

AGA and 2024 multi-society perioperative guidance favor individualized risk assessment. Patients without upper-GI symptoms who have followed fasting instructions often proceed without stopping therapy. Higher-risk patients may benefit from a liquid-only diet for 24 hours, delay until escalation symptoms resolve, or anesthesia precautions.

Ask the right preprocedure questions

Document the specific drug, dose, frequency, last dose, whether the patient is in dose escalation, and whether nausea, vomiting, early satiety, abdominal distention or severe constipation is present. Also identify diabetes, gastroparesis, Parkinson disease and other factors that may slow gastric emptying.

Practical clinical algorithm

Identify the GLP-1 drug, dose, last dose and whether the patient is in dose escalation.
Screen for nausea, vomiting, early satiety, bloating, abdominal pain and severe constipation.
Assess other causes of delayed gastric emptying and the planned depth of sedation.
For low-risk asymptomatic patients who complied with fasting, proceed under local protocol.
For higher-risk patients, consider 24-hour liquid diet, delay, ultrasound where available, or airway-protective anesthesia strategy.
Coordinate any medication interruption with the prescribing clinician, especially in diabetes.

Common mistakes to avoid

Automatically stopping every weekly GLP-1 drug for seven days.
Ignoring symptoms because standard fasting was followed.
Interrupting diabetes therapy without a glycemic plan.
Treating a patient in dose escalation as equivalent to a stable long-term user.
Proceeding with deep sedation despite strong evidence of retained gastric contents without modifying the plan.

Trainee takeaway

The safest strategy is not a universal stop rule; it is a structured assessment of gastric-retention risk, medication consequences and procedure urgency.

Frequently asked questions

Should all patients stop semaglutide before EGD?

No. Current guidance supports individualized management rather than universal cessation.

What is the highest-risk period?

The dose-escalation phase and periods of active GI symptoms are particularly important.

Can a liquid diet replace stopping the drug?

For selected higher-risk patients, a 24-hour liquid-only diet is one recommended risk-reduction option.

References

1. Thomson ABR. Clinical Pharmacology, Physiology and Pathophysiology: Gastroenterology, Hepatology, and Pancreaticobiliary Disorders. CAPstone Academic Publishers; 2024.

2. Thomson ABR. Practice Review in Gastroenterology. CAPstone Academic Publishers; 2014.

3. Al Hashash JG, Thompson CC, Wang AY. AGA Rapid Clinical Practice Update on the Management of Patients Taking GLP-1 Receptor Agonists Prior to Endoscopy. Clin Gastroenterol Hepatol. 2024.

4. Kindel TL, et al. Multi-society clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative period. Surg Endosc. 2024.

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions